According to the latest report by IMARC Group, titled “Brachytherapy Market Report by Service Type (History and Physical Report, Discharge Summary, Operative Note or Report, Consultation Report, and Others (Pathology Report, Radiology Report, etc.)), Technology (EMR/EHR, PACS, RIS, SRT, and Others), Mode of Procurement (Outsourcing, Offshoring, Both), End-User (Hospitals, Clinics, Clinical Laboratories, Academic Medical Centers, and Others), and Region 2025-2033”, the global brachytherapy market size reached USD 888.1 Million in 2024. Brachytherapy refers to a type of radiation therapy that is used to treat cancer. The procedure involves the placement of radioactive materials in or around the tumor to reduce the damage to the surrounding healthy tissue. Brachytherapy is effective in treating cervical cancer, breast cancer, skin cancer, and various other types of cancer. It can be utilized alone or in conjunction with other cancer treatments, including chemotherapy, surgery, and external radiation therapy. Brachytherapy allows doctors to deliver higher doses of radiation to specific body parts than conventional forms of radiation therapy or external beam therapy (EBT).
Global Brachytherapy Market Trends:
The global brachytherapy market is primarily driven by the increasing prevalence of different types of cancer. Brachytherapy uses artificially produced radionuclides, including Caesium-137, Iridium-192, Gold-198, Iodine-125, and Palladium-103, for routine use. This has resulted in the adoption of brachytherapy for the effective treatment of cancer. Apart from this, the increasing healthcare expenditure and rising awareness regarding the advanced treatment options for cancer are escalating the demand for brachytherapy. Besides this, there has been widespread acceptance of the therapy amongst patients and medical professionals as brachytherapy equipment offer extremely localized radiation doses to small tumors. They are also used for prophylactic, palliative, and curative treatments, and used as monotherapy or as an adjuvant with surgery. Furthermore, various research and development (R&D) activities and the development of minimally invasive surgical procedures are creating a positive outlook to the market. Looking forward, the market value is projected to reach USD 1,215.9 Million by 2033, expanding at a CAGR of 3.55% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Service Type, Technology, Mode of Procurement, End-User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Companies Covered | Acusis Software India Pvt Ltd., Transcend Services, Inc., Naunce Communications, Inc., MModal Global Services Pvt. Ltd., iMedX Information Services Pvt. Ltd., Global Medical Transcription LLC, nThrive Solutions LLC, MTBC (CareCloud, Inc.), Medi-Script Plus and Transtech Medical Solutions LLC |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal